Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
- Alternative title
-
Chimäre Antigen Rezeptor (CAR)-modifizierte T-Zellen gegen FLT3 bei Akuter Myeloischer Leukämie (AML)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Würzburg, Universität Würzburg, Dissertation, 2019
- Keyword
-
T cells
Protein-tyrosine kinase
Acute myeloid leukemia
Chimeric antigen receptor (CAR)
FMS-like tyrosine kinase 3 (FLT3)
FLT3 inhibitor
Acute myeloid leukemia (AML)
- Event
-
Veröffentlichung
- (where)
-
Würzburg
- (who)
-
Universität Würzburg
- (when)
-
2021
- Creator
-
Jetani, Hardikkumar
- Contributor
-
Hudecek, Michael
- DOI
-
10.25972/OPUS-17909
- URN
-
urn:nbn:de:bvb:20-opus-179096
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jetani, Hardikkumar
- Hudecek, Michael
- Universität Würzburg
Time of origin
- 2021
Other Objects (12)
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
FLT3-ITD regulated miRs in AML
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
FLT3 inhibitors in acute myeloid leukemia
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien
Dendritic Cell dysfunctions in AML patients with FLT3 ITD mutations
Charakterisierung von AML-assoziierten FLT3-Rezeptortyrosinkinasemutanten im Zell- und Mausmodell
Nachweis von NPM1- und FLT3-Mutationen bei Patienten mit AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
FLT3-ITD regulated miRs in AML
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
FLT3 inhibitors in acute myeloid leukemia
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien
Dendritic Cell dysfunctions in AML patients with FLT3 ITD mutations
Charakterisierung von AML-assoziierten FLT3-Rezeptortyrosinkinasemutanten im Zell- und Mausmodell
Nachweis von NPM1- und FLT3-Mutationen bei Patienten mit AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
FLT3-ITD regulated miRs in AML
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
FLT3 inhibitors in acute myeloid leukemia
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien
Dendritic Cell dysfunctions in AML patients with FLT3 ITD mutations
Charakterisierung von AML-assoziierten FLT3-Rezeptortyrosinkinasemutanten im Zell- und Mausmodell